Cabozantinib (XL184) targets VEGFR2, c-MET, KIT (also known as CD117), AXL, and FLT3; and induces apoptosis in FLT3-ITD+ leukemia cells in a dose-dependent manner [94,95]. This evidence concerns the gene AXL and leukemia.